Positioning As-needed Budesonide–Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2:

Eric D. Bateman, Paul M. O’Byrne, J. Mark FitzGerald, Peter J. Barnes, Jinping Zheng, Rosa Lamarca, Margareta Puu, Himanshu Parikh, Vijay Alagappan, and Helen K. Reddel

1 December, 2021

NZ Respiratory Research Review Issue 200

Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis–Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial :

Dinesh Khanna, Celia J. F. Lin, Daniel E. Furst, Bridget Wagner, Mauro Zucchetto, Ganesh Raghu, Fernando J. Martinez, Jonathan Goldin, Jeffrey Siegel, and Christopher P. Denton; for the focuSSced Investigators

1 December, 2021

NZ Respiratory Research Review Issue 201

Association of Psoriasis With Incident Venous Thromboembolism and Peripheral Vascular Disease:

Tai-Li Chen, MD; Ling-Ling Lee, PhD, RN; Huei-Kai Huang, MD; Jen-Hung Wang, MSc; Li-Yu Chen, BA; Hou-Ren Tsai, MD; Ching-Hui Loh, MD, PhD; Ching-Chi Chi, MD, MMS, DPhil

1 December, 2021

NZ Respiratory Research Review Issue 202

Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial:

Seth Toback, MD Eva Galiza, MBBS Catherine Cosgrove, PhD James Galloway, PhD Anna L Goodman, DPhil Pauline A Swift, PhD et al.

17 November, 2021

NZ Respiratory Research Review Issue 196

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial:

David P. Nichols, Alex C. Paynter, Sonya L. Heltshe, Scott H. Donaldson, Carla A. Frederick, Steven D. Freedman, Daniel Gelfond, Lucas R. Hoffman, Andrea Kelly, Michael R. Narkewicz, Jessica E. Pittman, Felix Ratjen, Margaret Rosenfeld, Scott D. Sagel, Sarah Jane Schwarzenberg, Pradeep K. Singh, George M. Solomon, Michael S. Stalvey, John P. Clancy, Shannon Kirby, Jill M. Van Dalfsen, Margaret H. Kloster, and Steven M. Rowe; for the PROMISE Study Group..

16 November, 2021

NZ Respiratory Research Review Issue 203

Impact of Time Between Diagnosis and Treatment for Nontuberculous Mycobacterial Pulmonary Disease on Culture Conversion and All-Cause Mortality:

Yunjoo Im, MD, PhD Na Young Hwang, PhD Kyunga Kim, PhD Hojoong Kim, MD, PhD O. Jung Kwon, MD, PhD Byung Woo Jhun, MD, PhD

15 November, 2021

NZ Respiratory Research Review Issue 199

Barriers and facilitators to best care for idiopathic pulmonary fibrosis in Australia:

Gabriella Tikellis, Tamera J. Corte, Alan K.Y. Teoh, Ian N. Glaspole, Sacha Macansh, Anne E. Holland

15 November, 2021

NZ Respiratory Research Review Issue 201

Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study:

Prof Nazir Ahmed Ismail, FCPath, Shaheed Vally Omar, PhD, Harry Moultrie, MBChB, Zaheda Bhyat, BTech, Francesca Conradie, MBChB, M Enwerem, MBBS et al.

12 November, 2021

NZ Respiratory Research Review Issue 199

Molecular Detection of Airborne Mycobacterium tuberculosis in South African High Schools:

Erick W. Bunyasi, Keren Middelkoop, Anastasia Koch, Zeenat Hoosen, Humphrey Mulenga, Angelique K. K. Luabeya, Justin Shenje, Simon C. Mendelsohn, Michele Tameris, Thomas J. Scriba, Digby F. Warner, Robin Wood, Jason R. Andrews, and Mark Hatherill

9 November, 2021

NZ Respiratory Research Review Issue 199

Effects of a Partially Supervised Conditioning Program in Cystic Fibrosis: An International Multicenter, Randomized Controlled Trial (ACTIVATE-CF):

Helge Hebestreit, Susi Kriemler, Christian Schindler, Lothar Stein, Chantal Karila, Don S. Urquhart, David M. Orenstein, Larry C. Lands, Jonathan Schaeff, Ernst Eber, and Thomas Radtke; on behalf of the ACTIVATE-CF Study Working Group

4 November, 2021

NZ Respiratory Research Review Issue 203